- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02652520
Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)
Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation
Kidney transplantation is the treatment of choice for end stage renal diseases, increasing life expectancy and quality of life. Improvement in organ preservation is a critical issue in this context.
This is a safety study evaluating the use of an oxygen carrier HEMO2Life® as an additive in organ preservation solution in kidney transplantation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Security of the use of HEMO2Life® will be analyzed by collecting all events within the first 3 months in terms of :
- HEMO2Life® adverse effects
- graft safety
- recipient safety (any adverse event) Accountability search will be achieved for each of these events.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29200
- CHRU Brest
-
Limoges, France, 87042
- Chu Limoges
-
Lyon, France, 69003
- Hôpital Edouard Herriot
-
Paris, France, 75013
- Hôpital La Pitié Salpêtrière
-
Poitiers, France, 86021
- CHU Poitiers
-
Tours, France, 37044
- CHRU de Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For Kidney :
The first ten local kidneys in each participating centers that do not meet the exclusion criteria.
- Graft retrieved in an adult donor
- Graft from a deceased donor after brain death (DBD)
- Graft locally transplanted in one of the 6 kidney transplant centers participating in the study
- Graft stored in preservation solution containing HEMO2Life®
For Patient :
Patient who signed an inform consent form In case of patient unable to signed an inform consent form for patient under judicial protection (supervision, guardianship) the inform consent form will be obtain from the patient himself and from the supervisor/guardianshiper/parents, they will signed together the patient inform consent form.
The probability of the inclusion of a patient unable to signed an inform consent form is low but we can't know the receiver before conditioning the graft.
Patient > 18 years old
Exclusion Criteria:
- Graft from a living donor
- Graft from a donor after cardiovascular death (DCD)
- Graft dedicated to a multi-organ transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Kidney transplantation
HEMO2Life® use in organ preservation solution.
Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
|
The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion.
The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company.
HEMO2Life® will then be added to preservation solution.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HEMO2Life® adverse effects
Time Frame: During 3 months
|
All incidents and events of interest occurring during the use of HEMO2Life® will be collected
|
During 3 months
|
Graft safety
Time Frame: During 3 months
|
Collecting any complication with particular attention to mascroscopic aspect, contamination of the conservation solution, surgical difficulties and thrombosis, primary non function, delayed graft function, slow recovery of graft function, acute rejection, or any other graft complications.
|
During 3 months
|
Recipient safety (any adverse event)
Time Frame: During 3 months
|
All adverse events, even unrelated to HEMO2Life®, occuring during the first 3 months after transplantation will be collected.
Vital signs and laboratory evaluations will be collected at D0, D1, D3, D7, D14, M1, M2 and M3 to evaluate the recipient safety
|
During 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the graft survival criteria with a control population
Time Frame: Baseline to 12 months
|
Results will be compared with patients from a case control group of grafts transplanted at the same time in the 4 transplant centers from the Spiesser group (Tours, Poitiers, Brest, Limoges).
Groups will be formed after matching on sex, age and cold ischemia time thanks to the Astre database regrouping the data of all the transplant teams from the Spiesser group.
|
Baseline to 12 months
|
Histological evaluation of the graft on biopsies
Time Frame: pre-implantation to 3-month biopsies
|
All biopsies are interpreted locally and classified according to the Banff classification.
Interstitial fibrosis quantification using automated quantitative image analysis of biopsies will also be performed from each biopsy.
|
pre-implantation to 3-month biopsies
|
Analysis of markers involved in kydney regeneration and neovascularization and markers of cellular stress.
Time Frame: Baseline to 12 months
|
Analysis of blood and urine biomarkers at each visit.
|
Baseline to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yannick LE MEUR, Principal Investigator and Nephrology coordinator
- Principal Investigator: Benoit BARROU, Urology coordinator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXYOP (RB 14.208)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Diseases
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
Peripal AGUniversity Hospital Birmingham NHS Foundation Trust; Swiss Federal Institute...CompletedRenal Failure | Peritoneal Dialysis | Renal Replacement Therapy | End Stage Renal Failure on Dialysis | End Stage Renal Disease on DialysisUnited Kingdom
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Sykehuset TelemarkOslo University HospitalActive, not recruitingQuality of Life | End Stage Renal Disease | End Stage Renal Failure on DialysisNorway
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Chinese University of Hong KongCompletedRenal Failure | End-stage Renal DiseaseHong Kong
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
Clinical Trials on HEMO2Life® use in organ preservation solution
-
Dr. F. Köhler Chemie GmbHActive, not recruiting
-
Klinikum FloridsdorfCompleted
-
Advanced Life SolutionsComplexo Hospitalario Universitario de A CoruñaCompleted
-
University Hospital, GhentJohnson & JohnsonCompleted
-
Abbott Medical DevicesTerminated
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
University of TwenteNot yet recruitingMelanoma (Skin)Netherlands
-
Allegro Ophthalmics, LLCDuke University; Trial Runners, LLCCompletedNon-Proliferative Diabetic RetinopathyUnited States
-
Drugs for Neglected DiseasesBayer; Bill and Melinda Gates FoundationCompleted
-
Aldeyra Therapeutics, Inc.Completed